Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -5.58%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong focus on successful clinical trial results and a solid financial position, despite increased expenses and net loss. The company is advancing its lead programs with significant progress in pipeline development.Company Guidance
During the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call, key guidance was provided on several metrics related to their development programs and financial results. The company reported a net loss of $110 million for the full year 2024 compared to $85.9 million in 2023, with research and development expenses increasing to $101.6 million from $63.8 million the previous year. Viking also highlighted significant progress in their pipeline, including successful results from trials such as the VK2735 Phase 2 VENTURE trial for obesity, which showed up to 14.7% reduction in body weight, and the VK2809 Phase 2b VOYAGE trial for NASH, demonstrating reductions in liver fat and improvements in fibrosis. Additionally, they raised over $630 million through a public stock offering, bolstering their financial position with $903 million in cash and equivalents as of year-end. The company plans to initiate Phase 3 trials for VK2735 in obesity in the second quarter of 2025 and advance other programs in its portfolio.Successful Clinical Trials Across Multiple Programs
Viking reported successful results from four studies across its pipeline, including VK2735 for obesity and VK2809 for NASH, achieving primary and secondary endpoints.
Strong Financial Position
Viking closed 2024 with over $900 million in cash, providing resources to advance its pipeline programs.
Positive Phase 2 VENTURE Trial Results for VK2735
The VENTURE trial achieved primary and secondary endpoints, with significant reductions in mean body weight from baseline up to 14.7%.
Advancement of VK2735 to Phase 3 Development
VK2735 advanced to Phase 3 development for obesity, with trials expected to initiate in the second quarter of 2025.
Positive Phase 1b Results for VK0214 in X-ALD
VK0214 demonstrated significant reductions in plasma levels of very long chain fatty acids and was safe and well tolerated.
---
VKTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VKTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $33.50 | $31.46 | -6.09% |
| Oct 23, 2024 | $60.39 | $73.22 | +21.25% |
| Jul 24, 2024 | $50.41 | $64.68 | +28.31% |
| Apr 24, 2024 | $65.07 | $68.86 | +5.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Viking Therapeutics (VKTX) report earnings?
Viking Therapeutics (VKTX) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Viking Therapeutics (VKTX) earnings time?
Viking Therapeutics (VKTX) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VKTX EPS forecast?
VKTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.33.
---